Asset profile
BNT168
Vaccine
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 59 same-indication; 49 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BNT168: this drug | Phase 1 | Vaccine | HIV antigens | ||
| AV000103A (ICVAX) | Phase 1 | Vaccine | HIV antigens | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | ||
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elvitegravir (Stribild / Genvoya (component)) | Approved | Small molecule | HIV integrase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | ||
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | ||
| Fosamprenavir (Lexiva / Telzir) | Approved | Small molecule | HIV protease | ||
| Fostemsavir (Rukobia) | Approved | Small molecule | HIV gp120 | ||
| Ibalizumab (Trogarzo) | Approved | Monoclonal antibody | CD4 receptor | ||
| Lenacapavir (Sunlenca / Yeztugo) | Approved | Small molecule | HIV capsid |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
February 2028 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.